LIXTE and its Collaborators Expand Clear Cell Ovarian Cancer Trial [Yahoo! Finance]
LIXTE and its Collaborators Expand Clear Cell Ovarian Cancer Trial
Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.'s $4.3 Million Registered Direct Offering [Yahoo! Finance]
Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.’s $4.3 Million Registered Direct Offering
Lixte Biotechnology Holdings, Inc. Announces $4.3 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules